These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 25930667)

  • 1. Emerging treatments in Neurogastroenterology: Perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases.
    Jarmuż A; Zielińska M; Storr M; Fichna J
    Neurogastroenterol Motil; 2015 Aug; 27(8):1057-68. PubMed ID: 25930667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome.
    Miner PB
    Expert Opin Pharmacother; 2018 Feb; 19(2):177-183. PubMed ID: 29376436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis.
    Shah ED; Kim HM; Schoenfeld P
    Am J Gastroenterol; 2018 Mar; 113(3):329-338. PubMed ID: 29380823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constella™(EU)-Linzess™(USA): the last milestone in the long journey of the peptide linaclotide and its implications for the future of peptide drugs.
    Góngora-Benítez M; Tulla-Puche J; Albericio F
    Future Med Chem; 2013 Mar; 5(3):291-300. PubMed ID: 23464519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.
    Busby RW; Bryant AP; Bartolini WP; Cordero EA; Hannig G; Kessler MM; Mahajan-Miklos S; Pierce CM; Solinga RM; Sun LJ; Tobin JV; Kurtz CB; Currie MG
    Eur J Pharmacol; 2010 Dec; 649(1-3):328-35. PubMed ID: 20863829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plecanatide for the treatment of constipation-predominant irritable bowel syndrome.
    Miner PB
    Expert Rev Gastroenterol Hepatol; 2020 Feb; 14(2):71-84. PubMed ID: 31985305
    [No Abstract]   [Full Text] [Related]  

  • 7. Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics.
    Forte LR
    Pharmacol Ther; 2004 Nov; 104(2):137-62. PubMed ID: 15518884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology and clinical potential of guanylyl cyclase C agonists in the treatment of ulcerative colitis.
    Pitari GM
    Drug Des Devel Ther; 2013; 7():351-60. PubMed ID: 23637522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guanylate Cyclase C: A Current Hot Target, from Physiology to Pathology.
    Uranga JA; Castro M; Abalo R
    Curr Med Chem; 2018; 25(16):1879-1908. PubMed ID: 29210639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guanylate cyclase-C receptor activation: unexpected biology.
    Brierley SM
    Curr Opin Pharmacol; 2012 Dec; 12(6):632-40. PubMed ID: 23131468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity
    Boulete IM; Thadi A; Beaufrand C; Patwa V; Joshi A; Foss JA; Eddy EP; Eutamene H; Palejwala VA; Theodorou V; Shailubhai K
    World J Gastroenterol; 2018 May; 24(17):1888-1900. PubMed ID: 29740204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders.
    Waldman SA; Camilleri M
    Gut; 2018 Aug; 67(8):1543-1552. PubMed ID: 29563144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plecanatide for Treatment of Chronic Constipation and Irritable Bowel Syndrome.
    Love BL
    Am J Med; 2019 May; 132(5):572-575. PubMed ID: 30550753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plecanatide: First Global Approval.
    Al-Salama ZT; Syed YY
    Drugs; 2017 Apr; 77(5):593-598. PubMed ID: 28255961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guanylin-Guanylyl cyclase-C signaling in macrophages regulates mesenteric fat inflammation induced by high-fat diet.
    Hasegawa K; Akieda-Asai S; Fujii Y; Bae CR; Yasuda M; Date Y
    Endocr J; 2015; 62(10):939-47. PubMed ID: 26249840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Algorithm for Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome Derived from a Canadian National Survey and Needs Assessment on Choices of Therapeutic Agents.
    Tse Y; Armstrong D; Andrews CN; Bitton A; Bressler B; Marshall J; Liu LW
    Can J Gastroenterol Hepatol; 2017; 2017():8612189. PubMed ID: 28271055
    [No Abstract]   [Full Text] [Related]  

  • 17. Plecanatide for the treatment of chronic idiopathic constipation in adult patients.
    Bassotti G; Usai Satta P; Bellini M
    Expert Rev Clin Pharmacol; 2019 Nov; 12(11):1019-1026. PubMed ID: 31575291
    [No Abstract]   [Full Text] [Related]  

  • 18. Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation.
    Vazquez Roque M; Camilleri M
    Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):301-10. PubMed ID: 21651347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guanylyl cyclase C signaling axis and colon cancer prevention.
    Pattison AM; Merlino DJ; Blomain ES; Waldman SA
    World J Gastroenterol; 2016 Sep; 22(36):8070-7. PubMed ID: 27688649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linaclotide: first global approval.
    McWilliams V; Whiteside G; McKeage K
    Drugs; 2012 Nov; 72(16):2167-75. PubMed ID: 23083112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.